GNH USA

Europe — EMA

Novantrone (Mitoxantrone Hydrochloride)

GNH USA supplies Novantrone (Mitoxantrone Hydrochloride), an antineoplastic agent for acute myeloid leukemia, metastatic prostate cancer and multiple

Mitoxantrone Hydrochloride

Request sourcing

1
Pack/s

What is Mitoxantrone Hydrochloride?

Mitoxantrone Hydrochloride, the active ingredient in Novantrone, is a Anthracenedone presented as a sterile powder for intravenous use. It is employed in the treatment of certain cancers, including acute myeloid leukemia and metastatic prostate cancer, and is also investigated off‑label for multiple sclerosis in adult patients.

GNH USA supplies Novantrone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics and timely delivery where required.

What is Mitoxantrone Hydrochloride used for?

Novantrone (mitoxantrone hydrochloride) is used in oncology and selected neurologic conditions to target rapidly proliferating cells.

Acute Myeloid Leukemia: Used as part of combination chemotherapy to achieve remission in adult patients. Metastatic Prostate Cancer: Administered to reduce disease progression in hormone‑refractory cases. Multiple Sclerosis (off‑label): Investigated to decrease relapse frequency in adults with progressive disease.

What are the side effects of Mitoxantrone Hydrochloride?

Novantrone may cause a range of adverse reactions, from frequent to rare but serious.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vomiting: occasional episodes. - Alopecia: reversible hair loss. - Myelosuppression: decreased white blood cells, red cells, and platelets.

Serious or Rare Side Effects: - Cardiotoxicity: reduced left ventricular function. - Secondary leukemia: therapy‑related acute leukemia. - Severe infection: due to profound neutropenia. - Pulmonary toxicity: interstitial pneumonitis.

What precautions apply to Mitoxantrone Hydrochloride?

When using Novantrone, several precautions should be observed to minimize risk. - Cardiac monitoring: baseline and periodic echocardiograms are recommended. - Hematologic monitoring: complete blood counts should be checked before each dose. - Liver function: assess hepatic enzymes prior to therapy and during treatment. - Pregnancy and lactation: avoid use; drug may cause fetal harm and is excreted in breast milk. - Drug interactions: review concomitant medications for potential additive myelosuppression. - Store at ambient temperature: keep in original container, protect from light and moisture.

What does Mitoxantrone Hydrochloride interact with?

Novantrone can interact with other medicines, affecting safety or efficacy.

Major Interactions (Avoid): - Anthracyclines: concurrent use increases risk of cardiotoxicity. - High-dose cyclophosphamide: may exacerbate myelosuppression. - Live vaccines: immunosuppression can lead to severe infection.

Moderate Interactions (Monitor Closely): - CYP450 inhibitors: may raise mitoxantrone plasma levels. - Anticoagulants: increased bleeding risk due to thrombocytopenia. - Radiation therapy: combined effect may enhance tissue toxicity.

Frequently asked questions

What conditions is Novantrone used to treat?+
Novantrone is indicated for the treatment of acute myeloid leukemia and metastatic prostate cancer. In addition, it is studied off‑label for multiple sclerosis in adult patients, where it may help reduce relapse frequency. These uses reflect its activity against rapidly dividing cells in both hematologic and solid‑tumor contexts.
How does Mitoxantrone Hydrochloride work?+
Mitoxantrone Hydrochloride intercalates into DNA and locks the DNA‑topoisomerase II complex, preventing the re‑ligation of DNA strands during replication. This creates double‑strand breaks that trigger apoptosis in proliferating cells, especially malignant leukemic and prostate tumor cells. Its immunosuppressive effect also modulates inflammatory pathways, supporting its off‑label use in multiple sclerosis.
What is the usual dose of Novantrone?+
The specific dose of Novantrone is determined by the prescribing clinician based on the patient’s condition, body surface area, and treatment protocol. Dosing regimens differ between acute myeloid leukemia, metastatic prostate cancer, and off‑label multiple sclerosis indications, and must be individualized by a qualified healthcare professional.
Is Novantrone safe during pregnancy or breastfeeding?+
The safety of Novantrone in pregnancy and lactation has not been established. Because the drug can cross the placenta and is excreted in breast milk, it is generally contraindicated for pregnant or nursing women. Physicians should discuss alternative therapies and advise avoidance of exposure during these periods.
How do I order Novantrone from GNH USA?+
To request Novantrone, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA supplies hospitals, pharmacies and procurement teams across international markets. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.
How does Novantrone compare with other antineoplastic agents?+
Novantrone belongs to the anthracenedone class, differing from anthracyclines such as doxorubicin in its DNA intercalation and topoisomerase II inhibition profile. While both classes share cardiotoxic risk, Novantrone’s immunosuppressive properties make it useful in multiple sclerosis, a use not typical for anthracyclines. Choice of therapy depends on disease type, prior treatment history, and individual risk factors.
How should Novantrone be stored and handled?+
Novantrone should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from light and moisture. The product must be kept in a secure, temperature‑controlled environment and handled by trained personnel using aseptic techniques to maintain sterility before intravenous administration.
How is Novantrone administered to patients?+
Novantrone is administered by intravenous infusion under the supervision of a qualified healthcare professional. The infusion is typically given over a defined period, often ranging from 30 minutes to several hours, depending on the treatment protocol and patient tolerance. Monitoring during infusion includes vital signs and observation for any immediate adverse reactions.
What are the most serious risks associated with Novantrone?+
The most serious risks of Novantrone include cardiotoxicity, which can lead to reduced left‑ventricular function, and the development of secondary, therapy‑related acute leukemia. Severe infections may also occur due to profound neutropenia, and pulmonary toxicity such as interstitial pneumonitis has been reported. Patients should be closely monitored for these events throughout therapy.
Who should not receive Novantrone?+
Novantrone should be avoided in patients with known severe cardiac disease, uncontrolled infections, or a history of hypersensitivity to anthracenedones. It is also contraindicated during pregnancy and breastfeeding, and in individuals with inadequate bone‑marrow reserve where further myelosuppression could be life‑threatening. Clinicians must assess each patient’s medical history before initiating therapy.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Mitoxantrone Hydrochloride
Route
Intravenous Use
Manufacturer
Viatris Medical
Origin
EU

Related products

Ebexantron

Ebexantron

Mitoxantrone Hydrochloride

Ebewe Pharma
EU
Mitoxantron Sandoz

Mitoxantron Sandoz

Mitoxantrone Hydrochloride

Sandoz B.V.
EU
Mitoxantrone Baxter

Mitoxantrone Baxter

Mitoxantrone Hydrochloride

Baxter Médico-Farmacêutica, Lda.
EU
Novantron

Novantron

Mitoxantrone Hydrochloride

Viatris Healthcare Gmbh
EU